166 related articles for article (PubMed ID: 37853824)
1. Intravenous iron supplementation improves energy metabolism of exercising skeletal muscles without effect on either oxidative stress or inflammation in male patients with heart failure with reduced ejection fraction.
Drozd MD; Tkaczyszyn M; Kasztura M; Węgrzynowska-Teodorczyk K; Flinta I; Banasiak W; Ponikowski P; Jankowska EA
Cardiol J; 2024; 31(2):300-308. PubMed ID: 37853824
[TBL] [Abstract][Full Text] [Related]
2. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
van Veldhuisen DJ; Ponikowski P; van der Meer P; Metra M; Böhm M; Doletsky A; Voors AA; Macdougall IC; Anker SD; Roubert B; Zakin L; Cohen-Solal A;
Circulation; 2017 Oct; 136(15):1374-1383. PubMed ID: 28701470
[TBL] [Abstract][Full Text] [Related]
3. Skeletal Muscle Abnormalities and Iron Deficiency in Chronic Heart Failure
Melenovsky V; Hlavata K; Sedivy P; Dezortova M; Borlaug BA; Petrak J; Kautzner J; Hajek M
Circ Heart Fail; 2018 Sep; 11(9):e004800. PubMed ID: 30354361
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
Ponikowski P; Kirwan BA; Anker SD; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Haboubi T; Keren A; Khintibidze I; Kragten H; Martinez FA; McDonagh T; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Jankowska EA
Eur J Heart Fail; 2019 Dec; 21(12):1651-1658. PubMed ID: 31883356
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh T; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD;
Eur Heart J; 2015 Mar; 36(11):657-68. PubMed ID: 25176939
[TBL] [Abstract][Full Text] [Related]
6. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design.
Mentz RJ; Ambrosy AP; Ezekowitz JA; Lewis GD; Butler J; Wong YW; De Pasquale CG; Troughton RW; O'Meara E; Rockhold FW; Garg J; Samsky MD; Leloudis D; Dugan M; Mundy LM; Hernandez AF;
Circ Heart Fail; 2021 May; 14(5):e008100. PubMed ID: 34003690
[TBL] [Abstract][Full Text] [Related]
7. Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF).
Yeo TJ; Yeo PSD; Hadi FA; Cushway T; Lee KY; Yin FF; Ching A; Li R; Loh SY; Lim SL; Wong RC; Tai BC; Richards AM; Lam CSP
ESC Heart Fail; 2018 Apr; 5(2):344-353. PubMed ID: 29345426
[TBL] [Abstract][Full Text] [Related]
8. Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency.
Charles-Edwards G; Amaral N; Sleigh A; Ayis S; Catibog N; McDonagh T; Monaghan M; Amin-Youssef G; Kemp GJ; Shah AM; Okonko DO
Circulation; 2019 May; 139(21):2386-2398. PubMed ID: 30776909
[TBL] [Abstract][Full Text] [Related]
9. Changes in myocardial iron content following administration of intravenous iron (Myocardial-IRON): Study design.
Miñana G; Cardells I; Palau P; Llàcer P; Fácila L; Almenar L; López-Lereu MP; Monmeneu JV; Amiguet M; González J; Serrano A; Montagud V; López-Vilella R; Valero E; García-Blas S; Bodí V; de la Espriella-Juan R; Sanchis J; Chorro FJ; Bayés-Genís A; Núñez J;
Clin Cardiol; 2018 Jun; 41(6):729-735. PubMed ID: 29607528
[TBL] [Abstract][Full Text] [Related]
10. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
[TBL] [Abstract][Full Text] [Related]
11. Effect of Ferric Carboxymaltose Supplementation in Patients with Heart Failure with Preserved Ejection Fraction: Role of Attenuated Oxidative Stress and Improved Endothelial Function.
Mollace A; Macrì R; Mollace R; Tavernese A; Gliozzi M; Musolino V; Carresi C; Maiuolo J; Nicita M; Caminiti R; Paone S; Barillà F; Volterrani M; Mollace V
Nutrients; 2022 Nov; 14(23):. PubMed ID: 36501086
[TBL] [Abstract][Full Text] [Related]
12. Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction.
López-Vilella R; Lozano-Edo S; Arenas Martín P; Jover-Pastor P; Ezzitouny M; Sorolla Romero J; Calvo Asensio M; Martínez-Solé J; Guerrero Cervera B; Sánchez Martínez JC; Donoso Trenado V; Sánchez-Lázaro I; Martinez Dolz L; Almenar Bonet L
ESC Heart Fail; 2022 Feb; 9(1):133-145. PubMed ID: 34964300
[TBL] [Abstract][Full Text] [Related]
13. Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial.
Santer P; McGahey A; Frise MC; Petousi N; Talbot NP; Baskerville R; Bafadhel M; Nickol AH; Robbins PA
BMJ Open Respir Res; 2020 Jun; 7(1):. PubMed ID: 32565444
[TBL] [Abstract][Full Text] [Related]
14. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
Comin-Colet J; Lainscak M; Dickstein K; Filippatos GS; Johnson P; Lüscher TF; Mori C; Willenheimer R; Ponikowski P; Anker SD
Eur Heart J; 2013 Jan; 34(1):30-8. PubMed ID: 22297124
[TBL] [Abstract][Full Text] [Related]
15. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
Ponikowski P; Filippatos G; Colet JC; Willenheimer R; Dickstein K; Lüscher T; Gaudesius G; von Eisenhart Rothe B; Mori C; Greenlaw N; Ford I; Macdougall I; Anker SD;
Eur J Heart Fail; 2015 Mar; 17(3):329-39. PubMed ID: 25683972
[TBL] [Abstract][Full Text] [Related]
16. Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
Anker SD; Ponikowski P; Khan MS; Friede T; Jankowska EA; Fabien V; Goehring UM; Metra M; Piña IL; Coats AJS; Rosano G; Dorigotti F; Comin-Colet J; Van Veldhuisen DJ; Filippatos GS; Butler J
Eur J Heart Fail; 2022 May; 24(5):833-842. PubMed ID: 35334136
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of the IRON-CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy.
Martens P; Dupont M; Dauw J; Somers F; Herbots L; Timmermans P; Verwerft J; Mullens W
ESC Heart Fail; 2019 Dec; 6(6):1208-1215. PubMed ID: 31562751
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON Trial.
Núñez J; Miñana G; Cardells I; Palau P; Llàcer P; Fácila L; Almenar L; López-Lereu MP; Monmeneu JV; Amiguet M; González J; Serrano A; Montagud V; López-Vilella R; Valero E; García-Blas S; Bodí V; de la Espriella-Juan R; Lupón J; Navarro J; Górriz JL; Sanchis J; Chorro FJ; Comín-Colet J; Bayés-Genís A;
J Am Heart Assoc; 2020 Feb; 9(4):e014254. PubMed ID: 32067585
[TBL] [Abstract][Full Text] [Related]
19. Ferric carboxymaltose in patients with heart failure and iron deficiency.
Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
[TBL] [Abstract][Full Text] [Related]
20. Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial.
Ambrosy AP; Lewis GD; Malhotra R; Jones AD; Greene SJ; Fudim M; Coles A; Butler J; Sharma A; Hernandez AF; Mentz RJ
J Cardiovasc Med (Hagerstown); 2019 Apr; 20(4):223-225. PubMed ID: 30540649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
